VivoSeq
Infectious Disease

Autoimmune Hepatitis

20

Pipeline Programs↗

3

Active Trials↗

11

Companies Involved↗

Autoimmune Hepatitis is an emerging landscape with 20 programs across 11 companies. The most active players are Bristol-Myers Squibb, TaiwanJ Pharmaceuticals Co., Ltd, Glaxo Dba Glaxosmithkline. 6 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

62/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 1T

TaiwanJ Pharmaceuticals Co., Ltd

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2S

Salix

1 program

Phase 2Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 2Novartis logo

Novartis

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

17 of 19 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody15%Protein / enzyme15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed8 · 40%
Terminated4 · 20%
Unknown status4 · 20%
Not yet recruiting2 · 10%
Withdrawn1 · 5%
Recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

Belimumab in Autoimmune Hepatitis
Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06381453·48 enrolled
Efficacy and Safety of Therapeutic Plasma Exchange vs Standard Medical Therapy in Severe Autoimmune Hepatitis.
Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06855667·50 enrolled
Induction of Remission in Autoimmune Hepatitis With Azathioprine vs. MMF
Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·Phase 2/3·NCT06650124·108 enrolled
Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Completed·TTaiwanJ Pharmaceuticals Co., Ltd·Phase 2·NCT02556372·20 enrolled
CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS
Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT01980745·61 enrolled
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT05476900·69 enrolled
Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial
Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT02463331·57 enrolled
sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS
Completed·—·Phase 1·NCT02239562·36 enrolled
Mycophenolate vs Azathioprin in Autoimmune Hepatitis
Completed·—·Phase 4·NCT00687180
Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis
Completed·—·Phase 2/3·NCT00838214·208 enrolled
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
Completed·KKezar Life Sciences, Inc.·Phase 2·NCT05569759·24 enrolled
Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis
Terminated·—·Phase 1·NCT04203875·1 enrolled
LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
Terminated·VVeloxis Pharmaceuticals·Phase 2·NCT00608894·13 enrolled
A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis
Terminated·SStero Biotechs Ltd.·Phase 2·NCT04129489·2 enrolled
Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)
Terminated·Roche logoRoche·Phase 2·NCT04790916·2 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)